BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Sagheddu C, Melis M, Muntoni AL, Pistis M. Repurposing Peroxisome Proliferator-Activated Receptor Agonists in Neurological and Psychiatric Disorders. Pharmaceuticals (Basel) 2021;14:1025. [PMID: 34681249 DOI: 10.3390/ph14101025] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 7.0] [Reference Citation Analysis]
Number Citing Articles
1 Calvier L, Alexander AE, Herz J. The “6B” Strategy: Build Back a Better Blood–Brain Barrier. Immuno 2022;2:506-511. [DOI: 10.3390/immuno2030032] [Reference Citation Analysis]
2 Fateh ST, Salehi-najafabadi A. Repurposing of substances with lactone moiety for the treatment of γ-Hydroxybutyric acid and γ-Butyrolactone intoxication through modulating paraoxonase and PPARγ. Front Pharmacol 2022;13:909460. [DOI: 10.3389/fphar.2022.909460] [Reference Citation Analysis]
3 Castro LVG, Gonçalves-de-Albuquerque CF, Silva AR. Polarization of Microglia and Its Therapeutic Potential in Sepsis. Int J Mol Sci 2022;23:4925. [PMID: 35563317 DOI: 10.3390/ijms23094925] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
4 Vallée A. Neuroinflammation in Schizophrenia: The Key Role of the WNT/β-Catenin Pathway. Int J Mol Sci 2022;23:2810. [PMID: 35269952 DOI: 10.3390/ijms23052810] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]